If you want your money back, the only way to do that is to turn a profit on PRAN. You might. Until then, wringing your hands doesn't do anything. So either sell and take a small loss, or hold. Whining is just irritating.
Maybe you bought it at $11 and watched it slide. Well, it is no longer at $11. There is much less chance to be burned, and much more potential upside.
Yes . . . that the families know . . and no. Alzheimer's sufferers can appear to get better for a wide variety of reasons -- better care, return to a familiar environment, etc. So individual experiences are suggestive. But only aggregate results are, in the end, what counts in getting a drug from phase 2 to phase 3.
The bottom line is: don't count your chickens before they have hatched.
A cautionary example: it used to be thought that if you cleared the amyloid proteins that caused plaque build-up, this would lead to cognitive improvement in Alzheimer's sufferers. That was the premise of the bapi trial. That trial FAILED to slow cognitive decline. In short, one can have a statistically significant result, but it is irrelevant to efficacy. In this particular case, I'd be interested to hear what an expert says, but I gather that PET scans are good for determining whether or not a person has Alzheimers (and not some other form of dementia), and reducing the "false positives" in such diagnosis. But addressing whether or not a person has the symptoms of Alzheimer's does not address what the causes are.
You are reading too much into the above. The only reasonably interpretations are 1) it says what is says 2) this means that there is NO problems with data input -- if there were, the DSMB would not be able to review unblinded data, as the data itself had not been locked.
That theory is a bit of a stretch. No, I will go further -- it is ridiculous. No management wants to look amateur, and no management wants to make it seem that they are abetting a conspiracy.
Someone, bored, seems to want to give thumbs down to the posting of scientific abstracts. Is Stash Fry back? A 10 year old?
Yes, the issue -- as many have stated many times -- is not how much it will increase on good/excellent results compared to today. The real issue is what is the company worth if it has a drug candidate that looks like it is going to market. Given the low valuation so far of this biotech, that eventual valuation has the potential to be far higher than $20/ share. Of course, we need to see good to excellent results.
From the press release, there is no indication of "botched" data. On the contrary, the unblinded data set seems fine.
The last update on Clinicaltrialsdotgov said that the trial was still "recruiting" as of December 2, 2013.
Smart move! I still have ALU (from $1.25) but have been thinking of selling as well as it is going sideways.
TRQ has dropped from the 11s all the way down to under 3, for a variety of reasons: delays in starting up operations and, more recently, conflicts with the Mongolian government. But it hit its bottom in terms of 50 DMA in December 2013. Since then it has been going up. This increase has nothing to do with rumors of buyout -- it is because concentrate was shipped, because the Mongolian government seems to realize that it has to come to some sort of modus vivendi with TRQ and, quite importantly, the ramping up of production targeted at a key market: China. This is not a mine like any other. Its major market is the 2nd largest economy in the world, China, which will have an insatiable need for copper and gold. And that market is right across the border.
Combined with an excellent opportunity for shorts to play on the fears of skittish investors. Just don't be skittish.
Actually, there is a tidbit of information in the press release that is quite important. It said that the DSMB had looked at the unblinded data. This tells us that the issue is not with data input or some data anomaly that had to be cleaned up. It may seem, in this day and age, when we aren't using pencils and manually inputting data, that there should not be data input problems. But they do happen. Not, howeve, with the NWBO data, which appears to be clean. We can strike off that possible reason for delat. The DSMB, in other words, has the final data, now all it needs to do is provide the analysis.